GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (FRA:LSRM) » Definitions » Institutional Ownership

CEL-SCI (FRA:LSRM) Institutional Ownership : 7.79% (As of Dec. 13, 2024)


View and export this data going back to 2000. Start your Free Trial

What is CEL-SCI Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CEL-SCI's institutional ownership is 7.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CEL-SCI's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CEL-SCI's Float Percentage Of Total Shares Outstanding is 97.30%.


CEL-SCI Institutional Ownership Historical Data

The historical data trend for CEL-SCI's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Institutional Ownership Chart

CEL-SCI Historical Data

The historical data trend for CEL-SCI can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 8.36 8.51 8.85 9.25 9.30 8.64 8.09 8.16 7.85 7.79

CEL-SCI Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


CEL-SCI Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI Headlines

No Headlines